Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.1
Commitments and Contingencies (Details Narrative)
1 Months Ended 3 Months Ended
Oct. 31, 2017
Nov. 30, 2019
USD ($)
Nov. 30, 2017
USD ($)
Nov. 30, 2016
USD ($)
ft²
Mar. 31, 2020
USD ($)
Dec. 31, 2019
Monthly lease payments         $ 56,429  
Alachua Facility [Member]            
Period of lease           5 years
Amended Lease Agreement [Member] | Minimum [Member]            
Monthly lease payments         $ 12,870  
Tampa Facility [Member]            
Period of lease   36 years   36 months    
Area of office space leased | ft²       2,207    
Lease expiry date       Feb. 29, 2020    
Tampa Facility [Member] | Minimum [Member]            
Monthly lease payments   $ 4,524   $ 4,138    
Tampa Facility [Member] | Maximum [Member]            
Monthly lease payments   $ 4,800   $ 4,392    
Lantibiotic Exclusive Channel Collaboration [Member]            
Royalty rate percenatge description     The Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company's election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program.      
Royalty payment of sublicenses percentage     25.00%      
Amount required to expended for advancement of lantibiotic program     $ 1,200,000      
Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member] | Amendment [Member]            
Royalty payment percentage     10.00%      
Lantibiotic Exclusive Channel Collaboration [Member] | Cost Of Revenue [Member]            
Royalty payment percentage     25.00%      
Lantibiotic Exclusive Channel Collaboration [Member] | Product Profit [Member]            
Reduction in royalty rate percentage     25.00%      
Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member]            
Reduction in royalty rate percentage     10.00%      
Lantibiotic Exclusive Channel Collaboration [Member] | New Drug Application [Member]            
Milestone payment under licensing agreement     $ 25,000,000      
Milestone measurement period     6 months      
Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]            
Milestone payment under licensing agreement     $ 25,000,000      
Milestone measurement period     6 months      
Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]            
Milestone payment under licensing agreement     $ 5,000,000      
Milestone measurement period     6 months      
Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]            
Milestone payment under licensing agreement     $ 5,000,000      
Milestone measurement period     6 months      
Oral Mucositis Exclusive Channel Collaboration [Member]            
Milestone payment under licensing agreement     $ 27,500,000      
Milestone measurement period     6 months      
Royalty rate percenatge description     The Company amended the Oral Mucositis ECC to: (i) consolidate the development milestone payments into one payment of $27,500,000 being due within six months after receiving FDA approval of a New Product Application; (ii) reduce the sublicense revenue percentage from 50% to 25% of sublicensing revenue; and (iii) revise the field in which the Company has exclusive rights to its Oral Mucositis product candidate for the treatment of Oral Mucositis to clarify that the Company has an exclusive for the treatment of Oral Mucositis in humans regardless of etiology.      
Royalty payment of sublicenses percentage 50.00%   25.00%      
Maturity of interest description         The Oral Mucositis ECC provides that in the event (i) Oragenics is required to make a milestone payment in cash as an issuance of shares would cause Precigen ActoBio to consolidate the Company's financial statements with Precigen ActoBio's financial statements, and (ii) Oragenics reasonably concludes that a cash milestone payment would have an adverse effect on its working capital needs over the next twelve (12) months, then such cash payment shall be in the form of an interest bearing promissory note with a maturity date of less than twelve (12) months and include other conventional market terms that would not be expected to unreasonably have an adverse effect on Oragenics working capital needs over such twelve (12) month period.  
Oral Mucositis Exclusive Channel Collaboration [Member] | Net Sales [Member] | Precigen ActoBio Inc [Member]            
Royalty payment percentage     12.00%      
Oral Mucositis Exclusive Channel Collaboration [Member] | Cost Of Revenue [Member] | Precigen ActoBio Inc [Member]            
Royalty payment percentage     25.00%      
Oral Mucositis Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]            
Milestone payment under licensing agreement     $ 27,500,000      
Milestone measurement period     6 months      
Oral Mucositis Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]            
Milestone payment under licensing agreement     $ 5,000,000      
Milestone measurement period     6 months      
Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]            
Milestone payment under licensing agreement     $ 5,000,000      
Milestone measurement period     6 months      
Amended Lease Agreement [Member] | Maximum [Member]            
Monthly lease payments         $ 13,338